Roche has received approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), in combination with chemotherapy, for the adjuvant treatment of adults with stage III deficient mismatch repair (dMMR) colon cancer.
The approval provides a new treatment option for patients following surgery and marks the 12th indication for Tecentriq in the United States. The treatment combines immunotherapy with a fluoropyrimidine and oxaliplatin-based chemotherapy regimen to help reduce the risk of cancer returning.
The FDA decision is based on results from the Phase 3 ATOMIC clinical trial, which evaluated Tecentriq alongside modified FOLFOX6 (mFOLFOX6) chemotherapy compared with chemotherapy alone in patients with stage III dMMR colon cancer.
The study found that adding Tecentriq to chemotherapy reduced the risk of disease recurrence or death by 50%. At 36 months, 86% of patients receiving Tecentriq plus chemotherapy were alive without disease recurrence, compared with 76% of those receiving chemotherapy alone.
The safety profile of the combination was consistent with previous studies of Tecentriq and mFOLFOX6, according to Roche.
“This approval provides a new adjuvant treatment option for people with stage III dMMR colon cancer who face a high risk of disease recurrence,” said Levi Garraway, Roche’s chief medical officer and head of global product development. He added that Tecentriq combined with chemotherapy could become a new standard of care for this patient group.
Frank A. Sinicrope, professor of oncology at the Mayo Clinic and US principal investigator for the ATOMIC trial, said the approval represents an important advance because it uses immunotherapy to target the specific biology of dMMR colon cancer after surgery.
Stage III colon cancer means the disease has spread to nearby lymph nodes but not to distant parts of the body. Treatment commonly includes surgery followed by chemotherapy. However, some patients experience a return of the disease despite receiving these treatments.
Deficient mismatch repair is a condition in which cells have difficulty correcting errors in their DNA. This can lead to a high number of genetic mutations in a tumour. These changes may make the cancer more likely to respond to immunotherapy, which helps the immune system recognise and attack cancer cells. dMMR is also associated with microsatellite instability-high (MSI-H) tumours.
Colon cancer remains a major global health concern, with more than one million people diagnosed worldwide each year. Around 15% of colon cancers have dMMR or MSI-H characteristics, according to Roche. The company also noted that recurrence remains a significant concern for people with stage III disease after surgery and chemotherapy.
Tecentriq is an immunotherapy that targets PD-L1, a protein that can help cancer cells avoid detection by the immune system. By blocking this protein, the medicine helps restore the immune system’s ability to attack cancer cells.
Roche said it is pursuing further regulatory applications, including with the European Medicines Agency, to make the treatment available to eligible patients in other regions.
The FDA approval expands the role of immunotherapy in early-stage cancer treatment and introduces a new option for patients with stage III dMMR colon cancer who face a risk of recurrence after surgery.